Correction: Hazzan et al. Thymic Stromal Lymphopoietin Interferes with the Apoptosis of Human Skin Mast Cells by a Dual Strategy Involving STAT5/Mcl-1 and JNK/Bcl-x_L. Cells 2019, 8, 829

• Error in Figure 3

In the original publication [1], there was a mistake in the published version of Figure 3a.

Dot plots from the same measurements were mistakenly used for different treatments. In Figure 3a, the treatments “w/o TSLP, non-targeting” and “w/o TSLP, STAT5-targeting” as well as “with TSLP, non-targeting” and “with TSLP, STAT5-targeting” originated from the same measurement.

In the original publication, there was also a mistake in the published version of Figure 3b.

The same error occurred here as described for Figure 3a; dot plots were assembled based on the same measurements and were mistakenly used to represent different treatments. In Figure 3b, the treatments “w/o TSLP, STAT5-targeting” (from Figure 3a) and “w/o TSLP, JNK-targeting” (from Figure 3b) as well as “with TSLP, STAT5-targeting” (from Figure 3a) and “with TSLP, JNK-targeting” (from Figure 3b) were apparently derived from the same measurement.

The same error occurred in Figure 3c; the same dot plots were mistakenly used for different treatments. The images “w/o TSLP, w/o STAT5-Inhibitor” and “w/o TSLP, with STAT5-Inhibitor” originated from the same measurement. This results in a noticeable similarity between the dot patterns.

The corrected version of Figure 3 appears below.

The original figure legend remains in place.

Figure 3. MC maintenance by TSLP critically depends on JNK and STAT5 activation. Impact of (a,c) STAT5 and (b,d) JNK perturbation on TSLP-promoted MC recovery (at 7.5 ng/mL) after 8 h, evaluated by the ratio of YoPro^TM-1 positivity (corresponding to the percentage of early and late apoptotic/necrotic cells combined) in TSLP-treated versus untreated MCs (described in methods). (a,b) Interference by Accell^®-mediated RNAi (48 h prior to TSLP treatment); (c,d) interference by specific inhibitors (STAT5 inhibitor: pimozide, JNK inhibitor: SP600125). Top: the results represent the mean ± SEM of six independent experiments. Bottom: representative flow cytometry dot plots (specified in red is the percentage of early and late apoptotic/necrotic cells combined); w/o—without. The data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001.

Figure 3. MC maintenance by TSLP critically depends on JNK and STAT5 activation. Impact of (a,c) STAT5 and (b,d) JNK perturbation on TSLP-promoted MC recovery (at 7.5 ng/mL) after 8 h, evaluated by the ratio of YoPro^TM-1 positivity (corresponding to the percentage of early and late apoptotic/necrotic cells combined) in TSLP-treated versus untreated MCs (described in methods). (a,b) Interference by Accell^®-mediated RNAi (48 h prior to TSLP treatment); (c,d) interference by specific inhibitors (STAT5 inhibitor: pimozide, JNK inhibitor: SP600125). Top: the results represent the mean ± SEM of six independent experiments. Bottom: representative flow cytometry dot plots (specified in red is the percentage of early and late apoptotic/necrotic cells combined); w/o—without. The data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001.

• Error in Figure 4

In the original publication, there was a mistake in the published versions of Figure 4c,d.

A pipetting error (the samples were applied in the wrong order, with 4 h first and then 2 h) contributed to the erroneous preparation of the images (rotation and shifting of the b-actin blot). In addition, membranes were mixed up, resulting in the use of non-corresponding ones for the target protein and the housekeeping protein.

Upon detailed inspection of all blots, these issues could be corrected.

The corrected version of Figure 4 appears below.

The original figure legend remains in place.

Figure 4. TSLP up-regulates Mcl-1 and Bcl-x_L. TSLP-induced expression (at 7.5 ng/mL) was studied by (a,b) reverse transcription - quantitative polymerase chain reaction (RT-qPCR) analysis of (a) Mcl-1 and (b) Bcl-x_L; normalized to the housekeeping gene Cyclophilin B. The results represent the mean ± SEM of nine independent experiments. The data were analyzed by the one-way Anova test with Tukey’s post-test for multiple comparisons, comparing each treatment (40′ or 90′) with the respective control group; * p < 0.05, ** p < 0.01; and (c,d) Western blot analysis using the indicated antibodies (shown are representative Western blots out of three independent experiments); the anti-β-Actin antibody served as loading control. Densitometry arbitrary units were normalized to the housekeeping protein.

Figure 4. TSLP up-regulates Mcl-1 and Bcl-x_L. TSLP-induced expression (at 7.5 ng/mL) was studied by (a,b) reverse transcription - quantitative polymerase chain reaction (RT-qPCR) analysis of (a) Mcl-1 and (b) Bcl-x_L; normalized to the housekeeping gene Cyclophilin B. The results represent the mean ± SEM of nine independent experiments. The data were analyzed by the one-way Anova test with Tukey’s post-test for multiple comparisons, comparing each treatment (40′ or 90′) with the respective control group; * p < 0.05, ** p < 0.01; and (c,d) Western blot analysis using the indicated antibodies (shown are representative Western blots out of three independent experiments); the anti-β-Actin antibody served as loading control. Densitometry arbitrary units were normalized to the housekeeping protein.

• Error in Figure 5

In the original publication, there was a mistake in the published version of Figure 5a.

The same error occurred here as described above for Figure 3a–c; the same measurements were mistakenly used to compile dot plots representing different treatments, such that in Figure 5a, the treatments “w/o TSLP, Mcl-1 targeting” and “with TSLP, Mcl-1 targeting” as well as “w/o TSLP, Bcl-xL targeting” and “with TSLP, Bcl-xL targeting” originated from the same measurement.

The corrected version of Figure 5 appears below.

The original figure legend remains in place.

Figure 5. Survival prolongation by TSLP depends on Mcl-1 and Bcl-x_L. Impact of Mcl-1 and Bcl-x_L knockdown on TSLP-promoted MC recovery (at 7.5 ng/mL), as evaluated by apoptosis reduction in TSLP-treated versus untreated MCs after 8 h. (a) Reduction of YoPro^TM-1-positivity (corresponding to the percentage of early and late apoptotic/necrotic cells combined) as mean ± SEM of nine independent experiments (left) and representative flow cytometry dot plots (right) (specified in red is the percentage of early and late apoptotic/necrotic cells combined); w/o—without; (b) reduction of caspase-3 activity as mean ± SEM of nine independent experiments. The data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001.

Figure 5. Survival prolongation by TSLP depends on Mcl-1 and Bcl-x_L. Impact of Mcl-1 and Bcl-x_L knockdown on TSLP-promoted MC recovery (at 7.5 ng/mL), as evaluated by apoptosis reduction in TSLP-treated versus untreated MCs after 8 h. (a) Reduction of YoPro^TM-1-positivity (corresponding to the percentage of early and late apoptotic/necrotic cells combined) as mean ± SEM of nine independent experiments (left) and representative flow cytometry dot plots (right) (specified in red is the percentage of early and late apoptotic/necrotic cells combined); w/o—without; (b) reduction of caspase-3 activity as mean ± SEM of nine independent experiments. The data were analyzed by paired t-test, ** p < 0.01, *** p < 0.001.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.